WuXi Biologics (Cayman) Inc. (WXIBF) reported a profit for its full year that Increases, from the same period last year
The company's bottom line came in at RMB4.908 billion, or RMB1.16 per share. This compares with RMB3.356 billion, or RMB0.78 per share, last year.
Excluding items, WuXi Biologics (Cayman) Inc. reported adjusted earnings of RMB5.640 billion or RMB1.33 per share for the period.
The company's revenue for the period rose 16.7% to RMB21.790 billion from RMB18.675 billion last year.
WuXi Biologics (Cayman) Inc. earnings at a glance (GAAP) :
-Earnings: RMB4.908 Bln. vs. RMB3.356 Bln. last year.-EPS: RMB1.16 vs. RMB0.78 last year.-Revenue: RMB21.790 Bln vs. RMB18.675 Bln last year.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.